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Abstract
In patients with inflammatory bowel diseases (IBD) 
the prevalence of thrombosis is 6.2%, the average in-
cidence of thromboembolism (TE) is 3.6 times higher 
compared to normal population. The TE is a common 
extraintestinal complication of IBD, squarely associ-
ated with the IBD activity. The application of antico-
agulant and thrombolytic therapy in severe IBD is an 
unresolved issue. Herein we report the first case in 
literature of an active IBD patient with an upper limb 
acute arterial occlusion and successful catheter-directed 
thrombolysis (CDT). A 46-year-old male patient is re-
ported who had Crohn’s disease for 10 years. His right 
hand suddenly became cold and painful. Angiography 
proved acute occlusion of the brachial and radial artery. 
Vascular surgery intervention was not applicable. En-
doscopy showed extended, severe inflammation of the 
colon. Despite the severe endoscopic findings, frequent 
bloody stools and moderate anaemia, CDT with recom-
binant tissue plasminogen activator was performed. 
The control angiography proved improvement, the 
radial artery pulse appeared. No bleeding complication 
was observed. This case supports that CDT-after care-
ful estimation of the bleeding risk-can be effective and 
safe in patients with severe or life-threatening TE and 
active IBD.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Crohn’s disease (CD) and ulcerative colitis (UC) the two 
main forms of  inflammatory bowel diseases (IBD) are 
systemic disorders often associated with extraintestinal 
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manifestations, complications, and other immune mediat-
ed disorders. These chronic inflammatory conditions are 
characterized by a hypercoagulable state and prothrom-
botic condition, and accompanied by abnormalities in co-
agulation. Thromboembolism (TE) is a significant cause 
of  morbidity and mortality in patients with IBD. Recent 
data suggest that TE is a disease-specific extraintestinal 
manifestation of  IBD, which is developed as the result 
of  multiple interactions between acquired and genetic 
risk factors. The incidence of  systemic thromboembolic 
events in IBD patients ranges from 1%-7.7%[1], patients 
having a 3-4-fold overall increase risk for venous TE 
compared to control population[2].
The application of  anticoagulant and thrombolytic 
therapy in severe IBD is an unresolved issue. Generally 
the management of  TE in IBD patients not differs from 
treatment in non-IBD patients, although there are cur-
rently no clear guidelines for the management of  IBD-
related TE[3]. 
CASE REPORT
A 46-year-old male with a past medical history of  10 
years’ CD, was presented with symptoms of  relapse of  
IBD: weight loss, lower abdominal pain, bloody diarrhoea 
and arthralgia (CD activity index: 345). He was treated 
with high dose prednisone due to severe activity of  IBD 
one year before this event. Actually he was on a treat-
ment with azathioprine (2.5 mg/bwkg) and mesalazine 
(3 g/d), on a stable dose during the last 1 year. He also 
complained about an acute onset of  pain and coldness 
of  his right hand. The physical examination revealed to 
an acute arterial occlusion of  the right hand. No provok-
ing factor could have been detected. The colour-Doppler 
imaging and the angiography proved the acute occlusion 
of  the right brachial and radial artery (Figure 1A and B). 
Vascular surgery intervention was not applicable. The 
laboratory findings showed anaemia (haemoglobin was 
85 g/L) and thrombocytosis (platelet count was 409 
g/L normal 150-400 g/L), the D-dimer test was posi-
tive (1.0 normal < 0.5 Feu/μL). Liver and kidney panels 
were normal. An acutely performed endoscopy showed 
extended, severe inflammation of  the colon with deep 
ulcers and signs of  chronic activity involving the sigmoid 
colon. Considering the severity of  the occlusion and the 
risk of  a potential limb-loss catheter-directed thromboly-
sis (CDT) was suggested, despite the severe endoscopic 
findings, frequent bloody stools and moderate anaemia. 
After 24 h from onset of  symptoms of  arterial occlusion 
endovascular arterial intervention was performed: 5 mg 
bolus of  recombinant tissue plasminogen activator (rt-PA) 
(Actilyse injection, Boehringer Ingelheim International) 
was injected into the thrombus, followed by a continuous 
rt-PA infusion through the catheter in a dose of  0.1 mg/
bwkg per hour. The treatment was carried on for 9 h and 
proceeded with enoxaparin (60 mg QD, subcutaneously). 
The pain and coldness quickly decreased, the radial pulse 
became palpable. The control angiography proved the 
improvement (Figure 1C and D). Despite the high risk of  
bleed no bleeding complication was observed. Echocar-
diography found no source of  an embolus. Low-molec-
ular-weight heparin (LMWH) prophylaxis was applied 
for 3 mo (enoxaparin, 60 mg OD, subcutaneously). No 
congenital thrombophilia was proved (antithrombin-Ⅲ: 
120% normal: 80-120; protein C: 132% normal: 70-130; 
protein S: 93% normal: 60-140; activated protein C re-
sistance: 2.51 normal: > 2; FVLeiden: wild type; Factor 
Ⅱ20210A: wild type; Factor Ⅷ: 188% normal: 60-150). 
Neither lupus anticoagulant nor antiphospholipid autoan-
tibody was detectable. The level of  homocystein was also 
normal. The relapse of  the CD was treated with anti-tu-
mor necrosis factor-α (anti-TNF-α) antibody (infliximab). 
One year after the biological treatment and continuous 
LMWH prophylaxis the patient is in remission of  IBD 
and has a complete recovery of  the right upper limb arte-
rial circulation.
DISCUSSION
We report a case of  a peripheral arterial TE of  the right 
upper limb in a 46-year-old patient with acute relapse of  
CD. In the background no provoking factors could have 
been detected. Thrombophilia evaluation was normal 
and a source of  an embolus was undetectable either. The 
background of  the hypercoagulability that is present in 
IBD is the altered platelet/endothel cell function and 
interaction, the elevated level of  coagulation factors and 
the decreased activity of  fibrinolysis. In patients with 
IBD the prevalence of  thrombosis is 6.2%, the average 
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Figure 1  Angiographic pictures. A: Occlusion of the right brachial; B: Occlu-
sion of the radial artery; C and D: Angiographic control after local thrombolytic 
treatment.
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incidence of  TE is 3.6 times higher compared to normal 
population[1]. TE events occur mainly in the venous circu-
lation[1,4], but can also develop in the arterial circulation[5]. 
Deep vein thrombosis and pulmonary embolism are the 
most common types of  TE, but thromboses are also 
reported in unusual sites such as cerebral, innominate, 
retinal, hepatic and mesenteric veins[2,6]. Arterial throm-
boembolic complications occur less frequently[7] and the 
majority of  cases seem to occur post surgery[8]. Patients 
with IBD have a markedly increased risk of  acute me-
senteric ischemia. IBD patients are more likely to have 
cardiac arterial thromboembolic disease, regardless of  
diagnosis or sex[9]. CD has an increased risk for cerebral 
arterial thromboembolic disease with some differences 
regarding the sex[10]. While the risk of  gastrointestinal 
bleeding has to be considered in each case, most patients 
tolerate anticoagulants at full dose. Thrombolytic therapy 
is generally preserved for massive, life-threatening throm-
bosis. So far, only 17 cases of  local thrombolytic treat-
ment in IBD patient have been reported[11,12]. Until now 
there has been no case reported about upper limb arterial 
occlusion and CDT in IBD. In conclusion, moderate-
severe active CD has to be considered as a risk factor for 
systemic TE[13]. Practice guidelines strongly recommend 
the use of  thrombosis-prophylaxis in active IBD[3]. Arte-
rial thrombosis is a rare, but severe complication of  IBD. 
Considering the severity of  the occlusion, in cases of  life-
threatening TE CDT could be an effective and safe inter-
vention.
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